在患有复发性/逆转性大B细胞淋巴瘤的患者中,NKTR-255增强了CD19 CAR-T后的完整反应
Sairah Ahmed1, John F DiPersio2, James H Essell3
1University of Texas, MD Anderson Cancer Center, Houston, Texas, United States.
Blood advances
|August 8, 2025
概括
在T细胞治疗后,NKTR-255改善了大型B细胞淋巴瘤患者的完整反应率. 这种试验性治疗是安全的,耐受性良好,这表明在复发性或耐药性LBCL中可能出现持久反应.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 血液学 血液学 血液学
背景情况:
- 自生CD19导向的仿制抗原受体 (CAR) T细胞疗法在复发/耐性大B细胞淋巴瘤 (LBCL) 中显示出高响应率.
- 然而,很大一部分患者会复发,因此需要采取提高长期疗效的策略.
- 这项研究研究NKTR-255作为一种辅助治疗,以改善CAR T细胞治疗结果.
研究的目的:
- 评估NKTR-255在CD19CAR T细胞治疗后在复发/耐药LBCL患者中使用的疗效和安全性.
- 评估NKTR-255对6个月完整反应率 (CR6) 和CAR T细胞再扩张的影响.
主要方法:
- 一个2期,随机,双盲,安慰剂控制,多中心研究.
- 15名患有R/RLBCL的患者接受了自基基 (axi-cel) 或自基基 (liso-cel) 的治疗.
- 11名患者被随机分配,接受NKTR-255 (不同剂量) 或安慰剂后CAR T细胞输液.
主要成果:
- NKTR-255增加了CR6率:NKTR-255组的73% (8/11) 与安慰剂组的50% (2/4) 相比.
- 临床反应与CD8+CAR T细胞再扩张相关.
- NKTR-255被很好地容忍,可控等级≥3的不良事件 (中性质减退,血小板减退,淋巴减退) 和没有报告的细胞因子释放综合征 (CRS) 或免疫效应细胞相关的神经毒性综合征 (ICANS).
结论:
- 在LBCL中,NKTR-255在CD19 CAR T细胞治疗后作为辅助疗法证明了安全性和耐受性.
- 该药物有效地增加了完整反应率和CAR T细胞持久性.
- 需要对NKTR-255与CAR T细胞和其他细胞疗法进行进一步的确认研究.
更多相关视频
08:04In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
11.9K
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.5K
相关概念视频
Cytotoxic T Cells-mediated Immune Response
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
